South Korea · Delayed Price · Currency is KRW Neuromeka Statistics
Total Valuation
Neuromeka has a market cap or net worth of KRW 361.66 billion. The enterprise value is 389.55 billion.
| Market Cap | 361.66B |
| Enterprise Value | 389.55B |
Important Dates
The last earnings date was Thursday, March 26, 2026.
| Earnings Date | Mar 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Neuromeka has 18.61 million shares outstanding. The number of shares has increased by 8.77% in one year.
| Current Share Class | 18.61M |
| Shares Outstanding | 18.61M |
| Shares Change (YoY) | +8.77% |
| Shares Change (QoQ) | +6.99% |
| Owned by Insiders (%) | 17.76% |
| Owned by Institutions (%) | 18.11% |
| Float | 15.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.26 |
| PB Ratio | 8.79 |
| P/TBV Ratio | 9.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 20.75 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.91, with a Debt / Equity ratio of 0.87.
| Current Ratio | 0.91 |
| Quick Ratio | 0.44 |
| Debt / Equity | 0.87 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.30 |
| Interest Coverage | -3.30 |
Financial Efficiency
Return on equity (ROE) is -125.86% and return on invested capital (ROIC) is -12.59%.
| Return on Equity (ROE) | -125.86% |
| Return on Assets (ROA) | -10.68% |
| Return on Invested Capital (ROIC) | -12.59% |
| Return on Capital Employed (ROCE) | -30.85% |
| Weighted Average Cost of Capital (WACC) | 16.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.21 |
| Inventory Turnover | 1.60 |
Taxes
In the past 12 months, Neuromeka has paid 66.31 million in taxes.
| Income Tax | 66.31M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +39.87% in the last 52 weeks. The beta is 2.25, so Neuromeka's price volatility has been higher than the market average.
| Beta (5Y) | 2.25 |
| 52-Week Price Change | +39.87% |
| 50-Day Moving Average | 24,558.00 |
| 200-Day Moving Average | 33,681.00 |
| Relative Strength Index (RSI) | 48.98 |
| Average Volume (20 Days) | 332,006 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Neuromeka had revenue of KRW 18.77 billion and -40.28 billion in losses. Loss per share was -2,323.19.
| Revenue | 18.77B |
| Gross Profit | 3.40B |
| Operating Income | -15.15B |
| Pretax Income | -40.30B |
| Net Income | -40.28B |
| EBITDA | -12.21B |
| EBIT | -15.15B |
| Loss Per Share | -2,323.19 |
Balance Sheet
The company has 8.75 billion in cash and 35.86 billion in debt, with a net cash position of -27.11 billion or -1,456.30 per share.
| Cash & Cash Equivalents | 8.75B |
| Total Debt | 35.86B |
| Net Cash | -27.11B |
| Net Cash Per Share | -1,456.30 |
| Equity (Book Value) | 41.14B |
| Book Value Per Share | 2,176.64 |
| Working Capital | -3.18B |
Cash Flow
In the last 12 months, operating cash flow was -12.56 billion and capital expenditures -3.01 billion, giving a free cash flow of -15.57 billion.
| Operating Cash Flow | -12.56B |
| Capital Expenditures | -3.01B |
| Depreciation & Amortization | 2.94B |
| Net Borrowing | 5.78B |
| Free Cash Flow | -15.57B |
| FCF Per Share | -836.61 |
Margins
Gross margin is 18.11%, with operating and profit margins of -80.72% and -214.55%.
| Gross Margin | 18.11% |
| Operating Margin | -80.72% |
| Pretax Margin | -214.68% |
| Profit Margin | -214.55% |
| EBITDA Margin | -65.05% |
| EBIT Margin | -80.72% |
| FCF Margin | n/a |
Dividends & Yields
Neuromeka does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.77% |
| Shareholder Yield | -8.77% |
| Earnings Yield | -11.14% |
| FCF Yield | -4.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 5, 2026. It was a forward split with a ratio of 1.5.
| Last Split Date | Aug 5, 2026 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
Neuromeka has an Altman Z-Score of 4.28 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.28 |
| Piotroski F-Score | 3 |